Agriculture and the Pharmaceutical Industry
In this policy brief, the Oakland Institute argues that “The enormous public resources invested in agriculture have benefited [pharmaceutical] companies by promoting the sale of [genetically engineered] seeds over and above their actual value and by allowing them to multiply their research efforts at minimal cost through collaborations with public institutions.” It’s an argument that I’ve seen before, although this is perhaps the most reader-friendly version that I’ve seen.
What I find interesting is the framing of subsidies as occuring through the (semi-)public works of “public-private partnerships and the patenting of university generated knowledge,” because it seems analogous to earlier public-works agricultural subsidies: that is, big water projects. What I also find interesting (and maybe it’s because of my relative newness to this field, and my focus more on the agricultural/environmental side of things) is its emphasis on the companies as part of the pharmaceutical industry, rather than on companies as part of Big Agriculture (which is more of what I see in the agricultural literature). I think this further highlights the importance of promoting dialogue between agricultural reform advocates (who often focus more on direct subsidies) and biotech patent reform advocates, as well as a reassessment of earlier public works projects and their unintended detrimental effects.